Advanced/Metastatic Solid Tumors Clinical Trial
Official title:
A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects With Advanced/Metastatic Solid Tumors
ADG206 is an activatable prodrug form of a fully human monoclonal antibody (mAb) of the immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137 (CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of advanced malignancies.
This is a FIH, Phase 1, open-label, multicenter, sequential dose escalation study to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary efficacy of ADG206 in subjects with advanced/metastatic malignancies. Primary Objective of the study: To assess safety and tolerability at increasing dose levels of ADG206 in subjects with advanced/metastatic solid tumors who have exhausted their treatment alternatives. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
| Active, not recruiting |
NCT04501276 -
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
|
Phase 1 | |
| Active, not recruiting |
NCT04182516 -
Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00996255 -
Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT02444793 -
A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03526835 -
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05718895 -
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03833427 -
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
|
Phase 1 | |
| Recruiting |
NCT04645069 -
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05607498 -
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05405595 -
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02665416 -
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01092052 -
Study of NMS-1116354 in Advanced/Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT05277402 -
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05394168 -
A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors
|
Phase 1 |